Skip to content

Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus

Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus, Question 3

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00829699
Enrollment
31
Registered
2009-01-27
Start date
2009-07-31
Completion date
2014-04-30
Last updated
2019-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

endothelial function, fibrinolytic balance

Brief summary

The purpose of this study is to learn more about why patients with diabetes have increased heart attacks, strokes and other illnesses due to blood clots causing blockage of a blood vessel. The proposed protocol will study the separate and combined effects of high glucose and high fats on certain cardiovascular responses in Type 2 DM.

Detailed description

Currently 75-80% of diabetes mellitus (DM) patients die due to thrombotic causes. Data from the Centers for Disease Control and Prevention released in 2000 indicated that mortality due to coronary artery disease is decreasing except in individuals with diabetes. Clearly the disordered metabolism, which includes abnormal metabolism of fats resulting in higher triglyceride and free fatty acid blood levels, occurring in diabetes predisposes these individuals to increased thrombotic events. Unless the underlying mechanisms responsible for these events can be identified, there will be an unprecedented number of diabetic patients suffering thrombotic episodes in the next 10 years. The specific aims of this study are to determine the effects of elevated free fatty acids and hyperglycemia (high glucose)on endothelial function and thrombolytic balance in patients with type 2 diabetes, and to determine the effects of increased insulin in this setting.

Interventions

PROCEDUREeuinsulinemic euglycemic glucose clamp

euinsulinemic euglycemic glucose clamp with lipid infusion 48 ml/hr for 4 hours

PROCEDUREeuinsulinemic hyperglycemic glucose clamp

euinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours

Hyperinsulinemic euglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours

PROCEDUREHyperinsulinemic hyperglycemic glucose clamp

Hyperinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
University of Maryland, Baltimore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* 16 Type 2 diabetic patients age 18 - 60 yrs * 16 Non-diabetic controls age 18-60 yrs * Body mass index \>20 kg/m2 * Female volunteers of childbearing potential: negative urine pregnancy test * Volunteers over 40 years old: an ECG with no clinically significant conduction or ischemic changes. * For those with type 2 diabetes: HBA1C \> 5.5% * For those with type 2 diabetes: C-peptide \>0.2 nmol, If C-peptide is abnormal or there is a clinical suspicion for type 1 diabetes, MODY or LADA, anti-islet cell and anti-GAD antibodies will be assessed to establish the diagnosis of type 2 diabetes vs. type 1/LADA/MODY. * PT (time) 12.8-14.6 seconds, PTT (time) 25-38 seconds

Exclusion criteria

* Any current disease condition that alters carbohydrate metabolism (other than type 2 DM) and/or evidence for clinically significant cardiac disease * Uncontrolled hypertension * Pregnancy * Subjects unable to give voluntary informed consent * Subjects with history of pancreatitis * Subjects on anticoagulant drugs, anemic, or with known bleeding diseases * Subjects with history of GI bleeding requiring treatment * Tobacco Use * Subjects with history of heparin-induced thrombocytopenia or heparin allergy * Subjects with severe egg or legume (soybean) allergy * Abnormal results following screening tests and physical examination that is clinically significant: Medical history/Physical Exam

Design outcomes

Primary

MeasureTime frame
Percent change in flow mediated dilation of brachial artery4 hours

Secondary

MeasureTime frame
Change in Lipid measures4hours

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026